Fluticasone Furoate

證據等級: L5

預測適應症: 8 個

Fluticasone Furoate: From Allergic Rhinitis to Atopic Eczema

One-Sentence Summary

Fluticasone furoate is an intranasal/inhaled corticosteroid internationally marketed for allergic rhinitis and (in combination with vilanterol) asthma/COPD; no Taiwan/US license record exists in this evidence pack. The TxGNN model predicts it may be effective for Atopic Eczema (Atopic Dermatitis), with 10 relevant clinical trials and 2 publications currently supporting this direction — though nearly all clinical evidence is drawn from the sister ester fluticasone propionate, not furoate itself. Evidence strength is limited (L3), and a Blocking safety data gap (missing TFDA/FDA label) means this remains at the Research Question stage.

Quick Overview

Item	Content
Original Indication	Allergic Rhinitis (intranasal corticosteroid class; no Taiwan/US license on record in this pack)
Predicted New Indication	Atopic Eczema
TxGNN Prediction Score	99.98%
Evidence Level	L3
US Market Status	Not Marketed
Number of NDAs	0
Recommended Decision	Research Question

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known information, fluticasone furoate belongs to the glucocorticoid receptor agonist (corticosteroid) class; its efficacy in allergic rhinitis and asthma/COPD has been proven, and mechanistically it may be applicable to atopic eczema through the same anti-inflammatory and anti-pruritic pathway.

Fluticasone furoate shares its parent structure with fluticasone propionate, which is already an approved and widely used topical treatment for atopic dermatitis. Both are potent, selective glucocorticoid receptor agonists that suppress inflammatory cytokines, eosinophil infiltration, and pruritus — the core pathology of atopic eczema. This shared mechanism is the basis of the TxGNN prediction.

However, the two esters are not interchangeable: they differ in skin penetration and receptor-binding potency, and fluticasone furoate currently has no marketed topical dermatological formulation (it exists only as a nasal spray and, combined with vilanterol, as an inhaler). The clinical trial and literature evidence below is therefore largely class-level (propionate) rather than furoate-specific, so this should be read as a same-class inference rather than direct proof.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00690105	Phase 4	Completed	577	Tacrolimus 0.1% vs. fluticasone (propionate) 0.005% ointment in adults with moderate-to-severe facial atopic dermatitis
NCT00689832	Phase 4	Completed	487	Tacrolimus 0.03% vs. fluticasone (propionate) 0.005% ointment in children ≥2 years with moderate-to-severe atopic dermatitis
NCT03742414	Phase 2	Active, not recruiting	398	SEAL study: proactive skin-barrier care plus fluticasone propionate cream to prevent early-infancy atopic dermatitis and food allergy
NCT01915914	Phase 4	Completed	107	Intermittent (twice-weekly) fluticasone propionate 0.05% cream plus daily moisturizer to reduce relapse risk in stabilized pediatric AD
NCT00616538	Phase 4	Completed	121	EpiCeram (non-steroidal barrier cream) vs. mid-strength fluticasone propionate 0.05% in pediatric moderate-to-severe AD
NCT00546000	Phase 4	Completed	56	Open-label study of Cutivate (fluticasone propionate) 0.05% lotion and effect on HPA axis in pediatric AD
NCT01772056	Phase 3	Terminated	54	Twice-weekly fluticasone propionate 0.05% cream maintenance to reduce relapse in mild/moderate AD in children
NCT07537751	N/A	Completed	40	Topical crisaborole 2% vs. fluticasone propionate 0.05% in mild-to-moderate pediatric AD
NCT00426283	Phase 2	Completed	42	Swallowed fluticasone propionate vs. placebo for eosinophilic esophagitis (different organ system; included for mechanistic reference only)
NCT03594565	Early Phase 1	Completed	13	Topical nasal steroids for skin reactions to CGM sensors in children with type 1 diabetes (small, indirect)

Note: All listed trials use fluticasone propionate, not furoate — no furoate-specific dermatological trial currently exists.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
40066386	2025	Case Report	Indian Journal of Otolaryngology and Head and Neck Surgery	Allergen immunotherapy use in a patient with autoimmune disease and atopic dermatitis; discusses corticosteroid-class management context
19571596	2009	Review	Neuroimmunomodulation	Intranasal corticosteroids and adrenal suppression, in patients with coexisting allergic rhinitis, asthma, and atopic dermatitis

US Market Information

No market authorization (NDA) is currently on record for fluticasone furoate in the jurisdiction covered by this evidence pack (market status: Not Marketed, 0 licenses).

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Research Question

Rationale: The prediction rests on a plausible same-class mechanistic link to fluticasone propionate rather than furoate-specific dermatological evidence, and no topical formulation of furoate currently exists — placing this at L3 evidence and the S1 (Research Question) decision stage.

To proceed, the following is needed:

TFDA/FDA label data (warnings, contraindications) — currently a Blocking data gap preventing any safety (S1) evaluation
Confirmed mechanism of action detail for fluticasone furoate specifically
Furoate-specific preclinical or clinical data in atopic dermatitis (current evidence is entirely propionate-based)
Feasibility assessment for a topical dermatological formulation, since furoate is only available as nasal/inhaled products today
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.